{"id":4677,"date":"2025-11-14T11:26:39","date_gmt":"2025-11-14T11:26:39","guid":{"rendered":"https:\/\/www.aicerts.ai\/news\/?post_type=news&#038;p=4677"},"modified":"2025-11-14T11:26:43","modified_gmt":"2025-11-14T11:26:43","slug":"generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs","status":"publish","type":"news","link":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/","title":{"rendered":"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-connects-science-medicine.jpg\" alt=\"Generative Therapeutics AI connects researchers to metabolic drug innovation.\"\/><figcaption class=\"wp-element-caption\">Generative Therapeutics AI bridges scientists and cutting-edge metabolic drug design.<\/figcaption><\/figure>\n\n\n\n<p>This article unpacks the announcement, market context, technical claims, and remaining risks for professional readers.<\/p>\n\n\n\n<p>Additionally, we explore financing moves, partnerships, and certification pathways relevant to multidisciplinary teams.<\/p>\n\n\n\n<p>Finally, we outline next steps for stakeholders tracking evidence, regulations, and data transparency.<\/p>\n\n\n\n<p>Recent advances in biomarker AI also influence how early signals are interpreted during candidate progression.<\/p>\n\n\n\n<p>Therefore, understanding these intersecting forces will help teams evaluate the announcement with balanced optimism.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cardiometabolic Market Demand Drivers<\/h2>\n\n\n\n<p>First, commercial dynamics explain Insilico\u2019s focus on obesity and diabetes.<\/p>\n\n\n\n<p>GLP-1 agonists already generate billions, and analysts predict continued double-digit growth this decade.<\/p>\n\n\n\n<p>In contrast, injectable peptides face pricing, supply, and adherence challenges.<\/p>\n\n\n\n<p>Consequently, oral small molecules designed with Generative Therapeutics AI promise convenient access and combination flexibility.<\/p>\n\n\n\n<p>Moreover, payers increasingly demand value evidence, fueling interest in biomarker AI that predicts responders earlier.<\/p>\n\n\n\n<p>These forces create fertile ground for Insilico\u2019s eight-asset debut.<\/p>\n\n\n\n<p>Demand, cost pressure, and adherence gaps converge within this market.<\/p>\n\n\n\n<p>Therefore, technology driven portfolios attract significant scrutiny, setting up our technical examination.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pharma.AI Engine Inner Insights<\/h2>\n\n\n\n<p>Pharma.AI blends Chemistry42, Biology42, and PandaOmics into an integrated design-make-test loop.<\/p>\n\n\n\n<p>Furthermore, cloud models generate millions of virtual structures, then prioritize syntheses using multi-objective scoring.<\/p>\n\n\n\n<p>Reports claim this approach cuts synthesis counts by 70%, supporting drug pipeline acceleration across disease areas.<\/p>\n\n\n\n<p>Subsequently, experimental automation validates predicted potency, selectivity, and pharmacokinetics.<\/p>\n\n\n\n<p>Generative Therapeutics AI sits at the core, iterating designs until oral bioavailability and safety windows align.<\/p>\n\n\n\n<p>Meanwhile, biomarker AI modules search transcriptomic and proteomic data to forecast target-engagement readouts.<\/p>\n\n\n\n<p>Taken together, these layers underpin claims of rapid, precise candidate generation.<\/p>\n\n\n\n<p>Algorithmic loops compress timelines yet still rely on empirical confirmation.<\/p>\n\n\n\n<p>Next, we inspect the resulting molecules.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Portfolio: Eight Program Snapshot<\/h2>\n\n\n\n<p>Insilico disclosed a diverse, oral portfolio spanning discovery to IND-enabling status.<\/p>\n\n\n\n<p>Key facts appear below.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Two GLP-1 receptor agonists deliver daily and weekly oral formats.<\/li>\n\n\n\n<li>NLRP3 inhibitor ISM8969: brain-penetrant, IND-enabling status.<\/li>\n\n\n\n<li>NR3C1 antagonist: improved pharmacokinetics over historical molecules.<\/li>\n\n\n\n<li>GIPR antagonist advancing through lead optimization.<\/li>\n\n\n\n<li>Dual amylin\/calcitonin agonist (DACRA) targeting satiety pathways.<\/li>\n\n\n\n<li>APJ biased agonist for metabolic remodeling.<\/li>\n\n\n\n<li>Lp(a) lowering small molecule addressing residual cardiovascular risk.<\/li>\n\n\n\n<li>All programs created through Generative Therapeutics AI and validated experimentally.<\/li>\n<\/ul>\n\n\n\n<p>Moreover, Insilico intends low-dose combinations to widen efficacy and safety margins.<\/p>\n\n\n\n<p>That strategy mirrors trends in obesity pipelines where multi-agonists outperform single agents.<\/p>\n\n\n\n<p>The snapshot illustrates broad target coverage and oral convenience.<\/p>\n\n\n\n<p>However, timeline speed claims require quantification, which we evaluate next.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Speed And Early Validation<\/h2>\n\n\n\n<p>Company materials state each preclinical nomination required only 12-18 months.<\/p>\n\n\n\n<p>Therefore, drug pipeline acceleration appears tangible compared with historic four-year averages.<\/p>\n\n\n\n<p>Rentosertib\u2019s Phase IIa data, published in Nature Medicine, support the approach.<\/p>\n\n\n\n<p>The highest dose added 98 mL FVC versus placebo in 71 patients.<\/p>\n\n\n\n<p>Consequently, investors view Generative Therapeutics AI as clinically validated, albeit in a different disease.<\/p>\n\n\n\n<p>Additionally, biomarker AI helped stratify responders within the trial, reinforcing mechanistic hypotheses.<\/p>\n\n\n\n<p>Early signals encourage, yet statistical power remains limited.<\/p>\n\n\n\n<p>Subsequently, IND filings for the cardiometabolic assets will mark the decisive test.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Partnerships And Financing Strategy<\/h2>\n\n\n\n<p>Insilico closed a $110 million Series E in March 2025.<\/p>\n\n\n\n<p>Moreover, collaborations with Lilly, Sanofi, Menarini, and EQRx supply non-dilutive capital and development expertise.<\/p>\n\n\n\n<p>These alliances de-risk Generative Therapeutics AI programs by sharing cost and regulatory responsibilities.<\/p>\n\n\n\n<p>Meanwhile, platform fees and milestone payments fund further drug pipeline acceleration.<\/p>\n\n\n\n<p>Consequently, investors anticipate multiple exit pathways, including licensing or public offerings.<\/p>\n\n\n\n<p>Additionally, professionals may validate skills via the <a href=\"https:\/\/store.aicerts.ai\/certifications\/specialization\/ai-nurse\/\">AI+ Nurse Certification<\/a> program.<\/p>\n\n\n\n<p>Cash and partnerships provide runway for expensive metabolic trials.<\/p>\n\n\n\n<p>Nevertheless, competition and reimbursement pressures could still squeeze margins, raising technical stakes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Challenges Caveats And Cautions<\/h2>\n\n\n\n<p>Independent reviews highlight data quality and model interpretability hurdles.<\/p>\n\n\n\n<p>In contrast, many promotional releases omit raw assay data, limiting reproducibility assessments.<\/p>\n\n\n\n<p>Therefore, skepticism persists until peer groups reproduce Generative Therapeutics AI outcomes in blinded studies.<\/p>\n\n\n\n<p>Regulators also request transparent model documentation, especially when biomarker AI guides patient stratification.<\/p>\n\n\n\n<p>Moreover, oral GLP-1 molecules must match peptide efficacy without triggering gastrointestinal toxicity.<\/p>\n\n\n\n<p>Competitive pressure compounds risk; Novo Nordisk and Lilly already advance several oral candidates.<\/p>\n\n\n\n<p>Consequently, Insilico must deliver clean safety margins and clear differentiation.<\/p>\n\n\n\n<p>Challenges span science, regulation, and competition.<\/p>\n\n\n\n<p>However, thoughtful mitigation could unlock outsized rewards, as discussed in the outlook.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Future Outlook And Actions<\/h2>\n\n\n\n<p>Insilico plans multiple IND submissions within 18 months, according to leadership interviews.<\/p>\n\n\n\n<p>Subsequently, first-in-human data will determine whether Generative Therapeutics AI truly outperforms conventional methods.<\/p>\n\n\n\n<p>Adaptive trial designs may further shorten feedback loops.<\/p>\n\n\n\n<p>Furthermore, platform licensing revenues can fund later-stage trials, maintaining optionality.<\/p>\n\n\n\n<p>Teams watching drug pipeline acceleration trends should monitor FDA filings, conference posters, and partner announcements.<\/p>\n\n\n\n<p>Milestone timing will clarify valuation and competitive positioning.<\/p>\n\n\n\n<p>Consequently, readers should prepare diligence frameworks before data packages emerge.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion<\/h3>\n\n\n\n<p>Insilico\u2019s cardiometabolic reveal demonstrates tangible progress for data-driven discovery.<\/p>\n\n\n\n<p>Generative Therapeutics AI compressed design cycles and produced orally available molecules across seven mechanisms.<\/p>\n\n\n\n<p>Clinical evidence, however, remains the decisive hurdle.<\/p>\n\n\n\n<p>Upcoming INDs, peer-reviewed datasets, and larger trials will confirm or challenge the narrative.<\/p>\n\n\n\n<p>Investors should track partnership structures, while clinicians review mechanistic differentiation and safety profiles.<\/p>\n\n\n\n<p>Meanwhile, development teams can pursue continuous learning through advanced credentials.<\/p>\n\n\n\n<p>Consequently, consider adding the <a href=\"https:\/\/store.aicerts.ai\/certifications\/specialization\/ai-nurse\/\">AI+ Nurse Certification<\/a> to deepen clinical AI expertise.<\/p>\n\n\n\n<p>Generative Therapeutics AI may redefine cardiometabolic care, and informed professionals will shape that outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Market excitement around metabolism drugs shows no sign of fading. Consequently, Insilico Medicine used its Pharma.AI stack to reveal eight oral candidates in November 2025. The disclosure, made at BIO-Europe, illustrates how Generative Therapeutics AI can reshape cardiometabolic discovery trajectories. Moreover, the portfolio spans GLP-1, GIP, amylin, NLRP3, NR3C1, Lp(a), and APJ targets. Investors, clinicians, and data scientists now question whether algorithmic design will translate into clinical and commercial wins.<\/p>\n","protected":false},"featured_media":4675,"parent":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"Generative Therapeutics AI","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.","_yoast_wpseo_canonical":""},"tags":[6307,6311,6312,6306,6310,6308,6309],"news_category":[4,1577],"communities":[],"class_list":["post-4677","news","type-news","status-publish","has-post-thumbnail","hentry","tag-biomarker-ai","tag-cardiometabolic-drugs","tag-clinical-validation","tag-drug-pipeline-acceleration","tag-generative-therapeutics-ai","tag-glp-1-oral-agonists","tag-pharma-ai-platform","news_category-ai","news_category-healthcare"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News<\/title>\n<meta name=\"description\" content=\"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News\" \/>\n<meta property=\"og:description\" content=\"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"AI CERTs News\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-14T11:26:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/\",\"url\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/\",\"name\":\"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News\",\"isPartOf\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg\",\"datePublished\":\"2025-11-14T11:26:39+00:00\",\"dateModified\":\"2025-11-14T11:26:43+00:00\",\"description\":\"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage\",\"url\":\"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg\",\"contentUrl\":\"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"A state-of-the-art lab scene visualizing Generative Therapeutics AI drug development.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.aicerts.ai\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.aicerts.ai\/news\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/#website\",\"url\":\"https:\/\/www.aicerts.ai\/news\/\",\"name\":\"Aicerts News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.aicerts.ai\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/#organization\",\"name\":\"Aicerts News\",\"url\":\"https:\/\/www.aicerts.ai\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.aicerts.ai\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.aicerts.ai\/news\/wp-content\/uploads\/2024\/09\/news_logo.svg\",\"contentUrl\":\"https:\/\/www.aicerts.ai\/news\/wp-content\/uploads\/2024\/09\/news_logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Aicerts News\"},\"image\":{\"@id\":\"https:\/\/www.aicerts.ai\/news\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News","description":"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News","og_description":"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.","og_url":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/","og_site_name":"AI CERTs News","article_modified_time":"2025-11-14T11:26:43+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/","url":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/","name":"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs - AI CERTs News","isPartOf":{"@id":"https:\/\/www.aicerts.ai\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage"},"image":{"@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg","datePublished":"2025-11-14T11:26:39+00:00","dateModified":"2025-11-14T11:26:43+00:00","description":"Explore how Generative Therapeutics AI propels eight Insilico cardiometabolic drugs, speeding discovery, fueling growth, and shaping strategy.","breadcrumb":{"@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#primaryimage","url":"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg","contentUrl":"https:\/\/aicertswpcdn.blob.core.windows.net\/newsportal\/2025\/11\/ai-lab-drug-discovery.jpg","width":1536,"height":1024,"caption":"A state-of-the-art lab scene visualizing Generative Therapeutics AI drug development."},{"@type":"BreadcrumbList","@id":"https:\/\/www.aicerts.ai\/news\/generative-therapeutics-ai-powers-insilicos-8-metabolic-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.aicerts.ai\/news\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.aicerts.ai\/news\/news\/"},{"@type":"ListItem","position":3,"name":"Generative Therapeutics AI Powers Insilico\u2019s 8 Metabolic Drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.aicerts.ai\/news\/#website","url":"https:\/\/www.aicerts.ai\/news\/","name":"Aicerts News","description":"","publisher":{"@id":"https:\/\/www.aicerts.ai\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.aicerts.ai\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.aicerts.ai\/news\/#organization","name":"Aicerts News","url":"https:\/\/www.aicerts.ai\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.aicerts.ai\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.aicerts.ai\/news\/wp-content\/uploads\/2024\/09\/news_logo.svg","contentUrl":"https:\/\/www.aicerts.ai\/news\/wp-content\/uploads\/2024\/09\/news_logo.svg","width":1,"height":1,"caption":"Aicerts News"},"image":{"@id":"https:\/\/www.aicerts.ai\/news\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/news\/4677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/types\/news"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/comments?post=4677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/media\/4675"}],"wp:attachment":[{"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/media?parent=4677"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/tags?post=4677"},{"taxonomy":"news_category","embeddable":true,"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/news_category?post=4677"},{"taxonomy":"communities","embeddable":true,"href":"https:\/\/www.aicerts.ai\/news\/wp-json\/wp\/v2\/communities?post=4677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}